Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | BLM | P54132 | 3/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25757649 | 0.86 | MAPT (0.48) | MAPTKDM4ENCOA1CYP3A4LMNA | |
| SCHEMBL28899699 | 0.78 | MKNK2 (0.33) | — | |
| SCHEMBL27896391 | 0.78 | MAPT (0.50) | MAPTKDM4ENCOA1CYP3A4LMNA | |
| SCHEMBL17375503 | 0.77 | MAPT (0.46) | MAPTKDM4ENCOA1CYP3A4LMNA | |
| SCHEMBL24855470 | 0.70 | TDP1 (0.39) | MAPTKDM4EBLMMEN1KMT2A | |
| SCHEMBL7658852 | 0.70 | KDM4E (0.48) | MAPTKDM4ENCOA1CYP3A4LMNA | |
| SCHEMBL3335156 | 0.67 | MAPT (0.48) | MAPTKDM4ENCOA1CYP3A4LMNA | |
| SCHEMBL1920170 | 0.67 | CA12 (0.42) | KDM4EERN1SMN1; SMN2 | |
| SCHEMBL13859959 | 0.66 | MAPT (0.71) | MAPTKDM4ENCOA1CYP3A4LMNA | |
| SCHEMBL217044 | 0.65 | MAPT (1.00) | MAPTKDM4ENCOA1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868060-A | Dihydropyridophthalazinone derivative, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2020-10-30 | — | — | CN | claimed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | claimed |
| US-12570651-B2 | Quinazoline-2,4-dione derivatives as PARP inhibitors | Suzhou Four Health Pharmaceuticals Co., Ltd. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-114206864-B | Quinazoline-2, 4-dione derivatives as PARP inhibitors | 苏州四体康宸医药科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2013097226-A1 | FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS | BEIGENE, LTD. (KY) | 2013-07-04 | — | — | WO | disclosed |
| EP-2533640-A1 | PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES | BioMarin Pharmaceutical Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2533640-A1 | PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES | BioMarin Pharmaceutical Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| CN-102834008-A | Processes of synthesizing dihydropyridophthalazinone derivatives | BIOMARIN PHARM INC | 2012-12-19 | — | — | CN | disclosed |
| CN-102834008-A | Processes of synthesizing dihydropyridophthalazinone derivatives | BIOMARIN PHARM INC | 2012-12-19 | — | — | CN | disclosed |
| US-20110196153-A1 | PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES | MEDIVATION, INC. | 2011-08-11 | — | — | US | disclosed |
| US-20110196153-A1 | PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES | MEDIVATION, INC. | 2011-08-11 | — | — | US | disclosed |
| WO-2011097602-A1 | PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097602-A1 | PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | MAPT 1463/4885KDM4E 2108/4885NCOA1 1458/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | MAPT 2382/4885KDM4E 737/4885NCOA1 585/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | MAPT 1124/4885KDM4E 4039/4885NCOA1 3791/4885 |
| US-12570651-B2 | Quinazoline-2,4-dione derivatives as PARP inhibitors | PARP1, PARP3, PARP2 | MAPT 562/4885KDM4E 2243/4885NCOA1 2487/4885 |
| US-20110196153-A1 | PROCESSES OF SYNTHESIZING DIHYDROPYRIDOPHTHALAZINONE DERIVATIVES | PARP1, PARP2, PARP8 | MAPT 1675/4885KDM4E 749/4885NCOA1 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.